April 8, 2026·5 min read·healing, soft-tissue, compound-overview
TB-500 — a research overview
Synthetic Thymosin Beta-4 analog with G-actin binding activity, cell-migration effects, and a mixed pre-clinical/cross-species literature.
TB-500 is a synthetic acetate of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found in thymic and other tissue. It operates through a fundamentally different mechanism than the GLP-1 class or the classical hormone-axis peptides: TB-500 binds and sequesters actin monomers (G-actin), modulating the pool available for cytoskeletal assembly and driving downstream effects on cell migration, differentiation, and tissue remodeling. The pre-clinical literature is substantial, albeit concentrated in specific tissue domains (cardiac repair, corneal healing, dermal wound healing, neuroregeneration). The human literature is sparser.
Mechanism
Thymosin Beta-4 was identified in the 1980s as an abundant protein in thymic epithelial cells, and its role in modulating actin dynamics was characterized in the 1990s and 2000s. The actin-binding function is the core mechanism: by sequestering G-actin, TB-500 alters the balance between monomeric and polymeric actin, affecting both the structural integrity of the cytoskeleton and the signaling cascades that depend on actin dynamics. This indirectly promotes cell migration (fibroblasts, endothelial cells, keratinocytes), drives angiogenesis via endothelial-cell mobilization, and enhances tissue remodeling in the context of injury.
The mechanism is distinct from growth-factor signaling — TB-500 is not engaging a receptor in the classical sense but rather modulating a structural substrate. This makes it mechanistically orthogonal to most other peptide classes and a logical pairing partner for other compounds.
Pharmacokinetics
TB-500 is considerably more thermolabile and shorter-lived than Semaglutide or other long-acting peptides. Terminal plasma half-life is on the order of 30 minutes to 2 hours, much shorter than GLP-1 agonists. However, much like BPC-157, the biological effects appear to outlast circulating levels, suggesting tissue-level accumulation or persistence. Pre-clinical work typically uses loading doses followed by maintenance schedules — for example, daily injections for 1–2 weeks, then every other week, with protocol variation depending on the model and endpoint.
Subcutaneous injection is standard in the literature. Bioavailability after injection is presumed high, but formal pharmacokinetic studies in humans are limited.
Cardiac: TB-500 administration post-myocardial infarction in rodent models is associated with improved left-ventricular ejection fraction, reduced scar area, and enhanced angiogenesis in the border zone. These effects are reproducible across multiple labs and appear robust.
Corneal and skin healing: In models of corneal abrasion and dermal wound repair, TB-500 accelerates epithelialization and improves architectural restoration. The mechanism appears to involve both angiogenesis and enhanced fibroblast and keratinocyte migration.
Neurological: Emerging pre-clinical work suggests TB-500 may enhance neuronal sprouting and synaptogenesis, though this is less mature than the cardiac and wound-healing literature.
The pre-clinical data is of reasonable quality, with multiple independent research groups reporting effects. The effect sizes are typically moderate to large (20–50% improvement in endpoints relative to controls).
The cross-species evidence problem
TB-500 has an unusual claim on human data: it appears in the veterinary literature, particularly in equine sports medicine, where it has been used off-label for soft-tissue injury in racehorses and performance horses. This provides a cross-species dose and response database — useful for dose scaling, but not a substitute for controlled human trials. Moreover, TB-500 is on the anti-doping list for equine competition, a regulatory status that reflects both its presumed biological activity and the acknowledgment that its effects are non-trivial.
Human RCT data for TB-500 is limited. Small open-label and case-series work exists, but no large powered Phase 2 or Phase 3 studies have been published. This is the largest evidence gap in the catalog relative to effect-size claims circulating on the internet.
Common research-protocol notes
TB-500 is almost never used in isolation in research protocols. The standard pairing is with BPC-157, forming the NF-020 blend. The two peptides address non-redundant mechanisms: TB-500 drives cell migration and actin remodeling, while BPC-157 drives angiogenesis and local inflammation modulation. The practical argument for pairing is strong — both are present in endogenous repair processes, and combining them mirrors the redundancy of natural healing rather than relying on a single pathway. See the healing peptides comparison for context on choosing between compounds.
Dosing in pre-clinical models is typically 1–5 micrograms per injection. Cross-species translation to humans is speculative; existing human work has ranged across similar magnitudes, but formal dose-response studies are absent.
Cycle timing varies by endpoint. For acute-injury repair protocols, loading and maintenance schedules span 4–12 weeks. For chronic soft-tissue support, indefinite low-frequency dosing is discussed but not well-studied.
Where it sits in the catalog
TB-500 (NF-001, NF-002, and as part of NF-020 blend with BPC-157) is the foundational soft-tissue repair peptide. Users interested in injury protocols typically start here, pairing it with BPC-157 for mechanistic breadth. The dual-peptide approach mirrors the endogenous repair toolkit and represents a distinct category from metabolic and growth-hormone agents elsewhere in the catalog.
